Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Indian CRAMS Players Scrambling For EU Market
According to pharma industry experts, outsourcing research and manufacturing of pharma products helps global pharma majors to reduce costs by almost 30-50%, due to the availability of talent
According to pharma industry experts, outsourcing research and manufacturing of pharma products helps global pharma majors to reduce costs by almost 30-50%, due to the availability of talent
Preclinical study was conducted at the Roswell Park Cancer Institute in Buffalo, New York, wherein Aptocine was used to treat primary tumors and examine prevention of metastases in
The projects will promote understanding of health issues such as diabetes, pain, severe asthma and psychiatric disorders, while enhancing the safety and efficiency of new medicines. The awards
Paul Vibert, general manager of Baxter China said: “the investment represents the company’s commitment to China and that he expects that the company can achieve double-digit sales growth
Medicis, a US based Aesthetics company, known for facial fillers like Restylane and Perlane will promote Dysport in the US as part of a sales agreement with the
Manufacturing a vaccine from the present strain of the virus entails some risk, as the virus is capable of mutating into a form that can turn the vaccine
In its complaint, Onyx seeks a declaration that fluoro-sorafenib is a jointly-owned collaboration compound under the Bayer/Onyx collaboration agreement, together with other remedies. Onyx affirmed that it continues
Architect CORE is a chemiluminescent microparticle immunoassay (CMIA) used to detect IgG and IgM antibodies to hepatitis B core antigen (anti-HBc). The company includes hepatitis B test to
SDSU researchers lead by Chandradhar Dwivedi, Head, Department of Pharmaceutical Sciences, SDSU have found that treating human skin cancer cells with various concentrations of sarcophine-diol has inhibited the
Alkermes, a biotechnology company, has initiated two new clinical trials of ALKS 33, an oral opioid modulator for the potential treatment of addiction and other nervous system disorders.